- BNF:
- 8.1.5
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- None
Comments
DO NOT PRESCRIBE (DNP)6: NICE TA 362: paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small cell lung cancer. (terminated appraisal. Decision date - November 2015)
RED1,2,3: NICE TA 389: paclitaxel in combination with platinum or as monotherapy is recommended as an option for treating recurrent ovarian cancer. (Decision date - May 2016)
RED1,2,3:NICE TA476 (replaces TA360) : paclitaxel as albumin-bound nanoparticles (nab-paclitaxel) with gemcitabine for untreated metastatic pancreatic cancer. (Decision date - Oct 2017)
Do Not Prescribe (DNP) Drug Classifications
- 6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again